Skip to content
10-K

Annual Report

Lipella Pharmaceuticals Inc. LIPO

0001753926-25-000507

← back to feed
Filed
Mar 28, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 26, 2025 2.55M sh
Shares Diluted FY 2024 · Dec 31, 2024 1.05M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 750.38K sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$3.95M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$3.15M
Cash And Equivalents FY 2024 · Dec 31, 2024 $2.18M
Cash And Equivalents FY 2024 · Dec 31, 2023 $3.29M
Stockholders Equity FY 2024 · Dec 31, 2024 $1.92M
Stockholders Equity FY 2024 · Dec 31, 2023 $3.14M
Stockholders Equity FY 2024 · Dec 31, 2022 $4.68M
Current Liabilities FY 2024 · Dec 31, 2024 $754.42K
Current Liabilities FY 2024 · Dec 31, 2023 $385.36K
Total Liabilities FY 2024 · Dec 31, 2024 $754.42K
Total Liabilities FY 2024 · Dec 31, 2023 $432.73K
Current Assets FY 2024 · Dec 31, 2024 $2.62M
Current Assets FY 2024 · Dec 31, 2023 $3.43M
Total Assets FY 2024 · Dec 31, 2024 $2.67M
Total Assets FY 2024 · Dec 31, 2023 $3.58M
Eps Diluted FY 2024 · Dec 31, 2024 −$4.79
Eps Diluted restated FY 2024 · Dec 31, 2023 −$6.16
Eps Basic FY 2024 · Dec 31, 2024 −$4.79
Eps Basic restated FY 2024 · Dec 31, 2023 −$6.16
Sga Expense FY 2024 · Dec 31, 2024 $2M
Sga Expense FY 2024 · Dec 31, 2023 $2.16M
Rd Expense FY 2024 · Dec 31, 2024 $3.61M
Rd Expense FY 2024 · Dec 31, 2023 $3.04M
Net Income FY 2024 · Dec 31, 2024 −$5.02M
Net Income FY 2024 · Dec 31, 2023 −$4.62M
Operating Income FY 2024 · Dec 31, 2024 −$5.08M
Operating Income FY 2024 · Dec 31, 2023 −$4.75M
Revenue FY 2024 · Dec 31, 2024 $536.36K
Revenue FY 2024 · Dec 31, 2023 $449.62K
Capex FY 2024 · Dec 31, 2023 $14.43K